Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection
Authors:
- Julie L. MitchellJMJulie L. Mitchell
- Justin PollaraJPJustin Pollara
- Kenneth DietzeKDKenneth Dietze
- R. Whitney EdwardsRER. Whitney Edwards
- Junsuke NoharaJNJunsuke Nohara
- Kombo F. N’guessanKNKombo F. N’guessan
- Michelle ZemilMZMichelle Zemil
- Supranee BuranapraditkunSBSupranee Buranapraditkun
- Hiroshi TakataHTHiroshi Takata
- Yifan LiYLYifan Li
- Roshell MuirRMRoshell Muir
- Eugene KroonEKEugene Kroon
Open Access
- 4 January 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (1)
Abstract
Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding of the HIV viral reservoir, but little is known about how the resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during the first 24 weeks of ART and correlated with Ab levels persisting after 48 weeks of ART. Participants treated in AHI stage 1 had lower Env-specific Ab levels and ADCC activity on ART than did those treated later. Importantly, participants who initiated ART after peak viremia in AHI developed elevated cross-clade ADCC responses that were detectable 1 year after ART initiation, even though clinically undetectable viremia was reached by 24 weeks. These data suggest that there is more germinal center (GC) activity in the later stages of AHI and that Ab development continues in the absence of detectable viremia during the first year of suppressive ART. The development of therapeutic interventions that can enhance earlier development of GCs in AHI and Abs after ART initiation could provide important protection against the viral reservoir that is seeded in individuals treated early in the disease.Keywords
Funding Information
- National Institutes of Health (R01AI108433)
- U.S. Department of War (WW81XWH-18-2-0040)
- Division of AIDS, National Institute of Allergy and Infectious Diseases (AAI20052001)
This publication has 67 references indexed in Scilit:
- A novel acute HIV infection staging system based on 4thgeneration immunoassayRetrovirology, 2013
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV InfectionPLOS ONE, 2012
- Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedJournal of Experimental Medicine, 2011
- An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 SerumJournal of Virology, 2011
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesJournal of Immunological Methods, 2011
- Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial ViremiaJournal of Virology, 2008
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C InfectionJournal of Virology, 2007
- Antibody neutralization and escape by HIV-1Nature, 2003
- Early events in lymph nodes during infection with SIV and FIVResearch in Virology, 1994